Literature DB >> 22213241

A method for analyzing the business case for provider participation in the National Cancer Institute's Community Clinical Oncology Program and similar federally funded, provider-based research networks.

Kristin L Reiter1, Paula H Song, Lori Minasian, Marjorie Good, Bryan J Weiner, Ann Scheck McAlearney.   

Abstract

BACKGROUND: The Community Clinical Oncology Program (CCOP) plays an essential role in the efforts of the National Cancer Institute (NCI) to increase enrollment in clinical trials. Currently, there is little practical guidance in the literature to assist provider organizations in analyzing the return on investment (ROI), or business case, for establishing and operating a provider-based research network (PBRN) such as the CCOP. In this article, the authors present a conceptual model of the business case for PBRN participation, a spreadsheet-based tool and advice for evaluating the business case for provider participation in a CCOP organization.
METHODS: A comparative, case-study approach was used to identify key components of the business case for hospitals attempting to support a CCOP research infrastructure. Semistructured interviews were conducted with providers and administrators. Key themes were identified and used to develop the financial analysis tool.
RESULTS: Key components of the business case included CCOP start-up costs, direct revenue from the NCI CCOP grant, direct expenses required to maintain the CCOP research infrastructure, and incidental benefits, most notably downstream revenues from CCOP patients. The authors recognized the value of incidental benefits as an important contributor to the business case for CCOP participation; however, currently, this component is not calculated.
CONCLUSIONS: The current results indicated that providing a method for documenting the business case for CCOP or other PBRN involvement will contribute to the long-term sustainability and expansion of these programs by improving providers' understanding of the financial implications of participation.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Year:  2011        PMID: 22213241      PMCID: PMC3323694          DOI: 10.1002/cncr.27375

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

1.  The business case for quality: case studies and an analysis.

Authors:  Sheila Leatherman; Donald Berwick; Debra Iles; Lawrence S Lewin; Frank Davidoff; Thomas Nolan; Maureen Bisognano
Journal:  Health Aff (Millwood)       Date:  2003 Mar-Apr       Impact factor: 6.301

2.  Medicine. The NIH Roadmap.

Authors:  Elias Zerhouni
Journal:  Science       Date:  2003-10-03       Impact factor: 47.728

3.  Translational and clinical science--time for a new vision.

Authors:  Elias A Zerhouni
Journal:  N Engl J Med       Date:  2005-10-12       Impact factor: 91.245

4.  US biomedical research: basic, translational, and clinical sciences.

Authors:  Elias A Zerhouni
Journal:  JAMA       Date:  2005-09-21       Impact factor: 56.272

5.  Models, strategies, and tools. Theory in implementing evidence-based findings into health care practice.

Authors:  Anne Sales; Jeffrey Smith; Geoffrey Curran; Laura Kochevar
Journal:  J Gen Intern Med       Date:  2006-02       Impact factor: 5.128

6.  Building community capacity to participate in cancer prevention research.

Authors:  Martha M McKinney; Bryan J Weiner; William R Carpenter
Journal:  Cancer Control       Date:  2006-10       Impact factor: 3.302

Review 7.  Practice-based research networks: laboratories for improving colorectal cancer screening in primary care practice.

Authors:  David Lanier
Journal:  Med Care       Date:  2008-09       Impact factor: 2.983

8.  Recruiting participants to cancer prevention clinical trials: lessons from successful community oncology networks.

Authors:  Martha M McKinney; Bryan J Weiner; Virginia Wang
Journal:  Oncol Nurs Forum       Date:  2006-09-01       Impact factor: 2.172

9.  Central challenges facing the national clinical research enterprise.

Authors:  Nancy S Sung; William F Crowley; Myron Genel; Patricia Salber; Lewis Sandy; Louis M Sherwood; Stephen B Johnson; Veronica Catanese; Hugh Tilson; Kenneth Getz; Elaine L Larson; David Scheinberg; E Albert Reece; Harold Slavkin; Adrian Dobs; Jack Grebb; Rick A Martinez; Allan Korn; David Rimoin
Journal:  JAMA       Date:  2003-03-12       Impact factor: 56.272

10.  Bridging the gap between basic science and clinical practice: a role for community clinicians.

Authors:  Katherine Kahn; Gery Ryan; Megan Beckett; Stephanie Taylor; Claude Berrebi; Michelle Cho; Elaine Quiter; Allen Fremont; Harold Pincus
Journal:  Implement Sci       Date:  2011-04-04       Impact factor: 7.327

View more
  4 in total

1.  Site selection for heart failure clinical trials in the USA.

Authors:  Matthew E Harinstein; Javed Butler; Stephen J Greene; Gregg C Fonarow; Norman L Stockbridge; Christopher M O'Connor; Marc A Pfeffer; Mandeep R Mehra; Scott D Solomon; Clyde W Yancy; Mona Fiuzat; Robert J Mentz; Sean P Collins; John J V McMurray; Muthiah Vaduganathan; Preston M Dunnmon; Giuseppe M C Rosano; Wilfried Dinh; Frank Misselwitz; Robert O Bonow; Mihai Gheorghiade
Journal:  Heart Fail Rev       Date:  2015-07       Impact factor: 4.214

2.  Challenges and facilitators of community clinical oncology program participation: a qualitative study.

Authors:  Ann Scheck McAlearney; Kristin L Reiter; Bryan J Weiner; Lori Minasian; Paula H Song
Journal:  J Healthc Manag       Date:  2013 Jan-Feb

3.  Why providers participate in clinical trials: considering the National Cancer Institute's Community Clinical Oncology Program.

Authors:  Ann Scheck McAlearney; Paula H Song; Kristin L Reiter
Journal:  Contemp Clin Trials       Date:  2012-08-19       Impact factor: 2.226

4.  Implementing community-based provider participation in research: an empirical study.

Authors:  Randall Teal; Dawn M Bergmire; Matthew Johnston; Bryan J Weiner
Journal:  Implement Sci       Date:  2012-05-08       Impact factor: 7.327

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.